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ABSTRACT
Background: While recent data show that crizotinib is highly effective in patients 
with ROS1 rearrangement, few data is available about the prognostic impact, the 
predictive value for different treatments, and the genetic heterogeneity of ROS1-
positive patients.
Patients and Methods: 1137 patients with adenocarcinoma of the lung were 
analyzed regarding their ROS1 status. In positive cases, next-generation sequencing 
(NGS) was performed. Clinical characteristics, treatments and outcome of these 
patients were assessed. Overall survival (OS) was compared with genetically defined 
subgroups of ROS1-negative patients.
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Results: 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The 
median OS has not been reached. Stage IV patients with ROS1-rearrangement had 
the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had 
at least one response to chemotherapy. Estimated mean OS for patients receiving 
chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement 
(52.6%) harbored additional aberrations.
Conclusion: ROS1-rearangement is not only a predictive marker for response 
to crizotinib, but also seems to be the one of the best prognostic molecular markers 
in NSCLC reported so far. In stage IV patients, response to chemotherapy was 
remarkable high and overall survival was significantly better compared to other 
subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.
INTRODUCTION
Non-small cell lung cancer (NSCLC) is still the 
leading cause of cancer-related death in the western world 
[1]. Nevertheless, the identification of therapeutically 
targetable oncogenic driver aberrations has led to an 
improvement on the clinical outcome of genetically 
defined subgroups of patients, like those harboring a 
sensitizing mutation within the epidermal growth factor 
receptor gene (EGFR) treated with EGFR-directed 
tyrosine kinase inhibitors (TKIs) or with rearrangements 
of the ALK oncogene treated with specific TKIs [2–6]. 
Additionally, improved molecular diagnostics led to a 
genomics-based classifications of NSCLC [7].
Chromosomal rearrangements involving the ROS1 
gene (c-ros oncogene 1) have recently been identified 
and described in 1–2% of patients with lung cancer [8, 
9]. ROS1 (chromosome 6q22) encodes a receptor tyrosine 
kinase which belongs to the insulin receptor family, with 
downstream signaling via the MAPK pathway through 
phosphorylation of RAS [10]. In lung cancer, ROS1 fusion 
partners include FIG, CD74, SLC34A2 and SDC4, which 
lead to oncogenic transformation and constitutive kinase 
activity in cell culture and/or in vivo [8, 11, 12]. So far, no 
ligand for the ROS1 tyrosine kinase has been identified.
Preclinical data suggest that ROS1 can be targeted 
by ALK inhibitors due to highly similar tyrosine kinase 
domains [13]. These findings together with the clinical 
notion that the cohort of ROS1-rearranged patients share 
features with ALK-rearranged patients led to the discovery 
that crizotinib is an effective treatment option with high 
response rates [9]. Nevertheless, few is known about the 
prognostic value, the clinical presentation, the predictive 
value for different therapy regimens, and the genetic 
heterogeneity in terms of multiplex-sequencing of patients 
harboring ROS1 rearrangement.
We set out this study in order to genetically and 
phenotypically identify patients with ROS1-rearranegments 
as part of an international, oligocentric prospective phase 
II trial to assess the response rates of patients with ROS1-
rearrangement treated with crizotinib (clinicaltrials.gov, 
NCT02183870), within a molecular screening network. 
The aim of this study was to detect the prevalence and 
incidence of ROS1 rearrangement in these patients, to 
analyze specific features of ROS1 rearrangement detection 
by fluorescence in situ hybridization (FISH), to describe 
their clinical and pathological characteristics, to assess 
co-occurring mutations measured by high-standard 
techniques (next-generation sequencing [NGS]), and to 
compare stage IV ROS1-positive patients with stage IV 
patients with other defined genetic aberrations regarding 
survival (i.e. EGFR, EML4-ALK, FGFR1, KRAS).
RESULTS
ROS1-rearrangement patterns
The majority of the samples were biopsy specimens 
(i.e. core needle biopsies, ultrasound-guided transbronchial 
biopsies and cytology specimens). Of all ROS1-rearranged 
cases, only 1 sample was material from total tumor 
resection lobectomy. None of the ROS1 rearranged cases 
was a cytology specimen (i.e. blocked material from fine 
needle aspiration).
ROS1 status was evaluable in 1035 out of 1137 
(91.0%) patients, whereof 19 patients (1.8%) had a ROS1 
rearrangement. ROS1 signals were homogeneously distri-
buted in all analyzed tumors. The amount of cells showing 
aberrant signals ranged between 23% and 100% (mean 
66%, median 67%). In all rearranged cases we observed an 
even signal distribution over the entire tumor with no “hot 
spot” areas. However, among different rearranged tumors, 
we observed a certain variation in the signal patterns. Some 
tumors showed only additional 3’ signals with no or few split 
signals, indicating an unbalanced translocation. In contrast, 
other tumors showed a homogenous split signal pattern in all 
tumor cells (see Figure 1).
Clinical presentation
10 patients were male and 9 patients female. 
A summary of the clinical characterization is given in 
Table 1. The median age at diagnosis was 60 years (range, 
26–87). In one patient, there were partially neuroendocrine 
patterns in the tumor. The majority of patients presented 
with stage IV disease at diagnosis (n = 14). 13 patients 
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Figure 1: (A) ROS1-rearranged case with clear split signals and additional green signals. (B) ROS1-rearranged case with primarily 
additional green signals and few clear split signals. (C) ROS1-rearranged case with only additional green signals indicating an unbalanced 
translocation.
Table 1: Clinical characteristics of patients with ROS1-rearrangement (n = 19)
Characteristics Number of patients Years %
Age at diagnosis
 Mean
 Standard deviation
 Median
 Range
19
58.6
14.8
60
26–82
100
Gender
 Women
 Men
9
10
47.4
52.6
Smoking
 Never
 Former
 Current
13
3
3
68.4
15.8
15.8
UICC tumor stage
 I
 II
 III
 IV
2
0
3
14
10.5
0
15.8
73.7
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(68.4%) were never-smokers, whereas 3 were active 
smokers and 3 patients had a smoking history. Patients 
with smoking history had a median of 40 pack-years 
(range, 30–45). The clinical and pathological presentation 
of each patient is listed in Table 2.
Co-occurring mutations detected by NGS
15 of the 19 (78.9%) detected patients could 
further be analyzed by NGS. In 7 (46.7%), aberrations 
within the TP53 gene were detected: 5 patients (33.3%) 
had the P72R-polymorphism, whereof one patient 
had also a E204* mutation, and one patient had a 
K305* as the only additional aberration. One patient 
had a R248L mutation co-occurring with a MAP2K1 
missense mutation (K57N). Of the P72R patients, 
one had an EGFR mutation in exon 21 (P848L). All 
TP53 alterations were either known polymorphisms or 
inactivating and truncating mutations.
2 out of 17 patients analyzed with NGS or by Sanger 
sequencing (11.8%) had BRAF mutations (G469S and 
an intron mutation c.1742–1 G > T, p.? which has not 
been described yet). One patient (6.7%) showed a MET 
mutation (R988C), located within the juxtamembrane 
region. Taken together, in 10 of 15 (66.7%) patients 
analyzed by NGS, further genetic aberrations were 
detected (see Table 2). Both BRAF mutations occurred in 
patients with a smoking history.
Table 2: Line listing of the patients
Pat ID Gender Age 
(years)
Initial 
stage
ROS1 
transl. 
(%)
Additional 
genetic 
aberration
Further 
analyzed
Pack-
years
Systemic 
therapy 
lines – CTX
BR 
CTX
Best 
response 
CTX under
BR 
crizotinib
Overall 
survival 
(months)
02 m 69 IV 100 - ALK FISH 45 2 n/a n/a n/a 36.72
03 m 55 IV 100 TP53 P72R NGS 0 8 PR
CARBO/
GEM/BEV 
(3x)
PR 63.64*
04 m 62 IV 23 - NGS 30 1 SD CARBO/PEM n/a 6.79*
05 m 50 IV 25 EGFR P848L, TP53 P72R NGS 0 1 n/a n/a n/a 1.41*
06 m 56 IV 25 - NGS, 
HER2 FISH
0 1 PR CIS/PEM n/a 12.20*
07 m 78 IIIB 50 TP53 E204*, TP53 P72R NGS 0 1 PD n/a n/a 4.13
08 f 26 IV 62 TP53 K305* NGS, 
HER2 FISH
0 2 PD n/a n/a 2.95
09 m 52 IA 76 - NGS 30 n/a n/a n/a n/a 16.59*
10 f 61 IIIB 83 TP53 P72R NGS 0 1 PR (RCTX) n/a 12.75*
11 m 31 IV 100 - NGS 0 1 PR CIS/PEM/
BEV
n/a 21.25*
12 f 87 IV 55 MET R988C NGS, 
HER2 FISH
0 1 PR GEM n/a 3.77*
13 f 62 IA 65 BRAF G469S NGS 40 n/a n/a n/a n/a 41.64*
14 f 69 IV 67 TP53 P72R NGS 0 1 PR
CARBO/
PACLI/
BEV
PR 13.34*
15 f 54 IIIA 95 - ALK, RET 
FISH
0 n/a n/a n/a n/a 3.08
16 f 50 IV 96 - NGS 0 5 PR GEM/CET, 
DOCE/CET
PR 78.59*
17 m 78 IV 74 BRAF 
c.1742–1G>T
NGS 40 1 SD PEM n/a 3.02*
18 m 62 IV 26
MAP2K1 
K57N, TP53 
R248L
NGS 40 1 SD PEM n/a 5.11*
(Continued )
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In all four patients without NGS analysis the ALK 
status analysis was performed using FISH. None of them 
harbored a translocation. RET status was negative in the 
two patients analyzed. Sanger sequencing did not reveal 
any other genetic aberrations.
Survival analysis
Median follow-up time (see supplementary data) 
was 16.6 months (95% CI, 9.3–23.9 months). For patients 
with ROS1-rearrangement, the median OS was not 
reached (see Figure 2A). The estimated mean survival 
time was 51.1 months (95% CI, 32.1–70.0 months).
Patients with stage IV (n = 14) were further 
compared with 115 stage IV patients comprising 38 
patients with EGFR mutation treated with erlotinib and/or 
gefitinib and/or afatinib (+/− cetuximab), 13 patients with 
ALK rearrangement treated with crizotinib and/or ceritinib, 
32 patients with KRAS mutations and 32 patients with 
squamous-cell carcinoma and FGFR1 amplification (see 
Supplementary Figure 1). Survival for the ROS1-positive 
patients was significantly better than in the comparison 
group (36.7 months vs 17.5 months, p = 0.005). Median 
overall survival for the ROS1-patients who did not receive 
crizotinib treatment (n = 9) was 36.7 months, whereas 
the median for the five patients receiving crizotinib has 
not been reached (estimated mean OS, 65.9 months [95% 
CI, 44.3 – 87.5 months], see Supplementary Figure 2). 
Due to the small sample-size and the low prevalence of 
events, no statistical significance between ROS1 stage IV 
patients with or without crizotinib treatment (p = 0.279, 
see supplement) could be found.
Compared with genetically predefined subgroups, 
patients with ROS1-rearrangement had the best OS (p ≤ 
0.001, see Figure 2B and Table 3). OS was significantly 
prolonged compared to EGFR-mutated patients (36.7 vs. 
25.3 months, p = 0.047) and to ALK-rearranged patients 
(36.7 vs. 23.9 months, p = 0.026), both treated with target-
specific therapy. Taken both, EGFR-positive and ALK-
positive patients together, their OS was 24.2 months (95% 
CI, 20.9–27.5 months) and remained significantly shorter 
than for ROS1-rearranged patients (p = 0.033).
Treatment outcomes
Of the 14 stage IV patients, 12 were evaluable 
for outcome analysis (one had an individual treatment 
approach with combining systemic therapy with local 
procedures, one was lost to follow-up after irradiation of 
cerebral metastasis). Two stage IIIB patients were taken 
into analysis. The 14 patients received between one and 8 
chemotherapy lines respectively (median = 1, see Table 2). 
Of them, 9 patients (64.3%) had at least one radiological 
response to chemotherapy, 3 (21.4%) had stable disease 
as best outcome and 2 (14.3%) did not respond to 
chemotherapy (see Supplementary Figure 3A). Table 2 
shows the different outcomes of the patients. Both patients 
not responding to treatment had additional truncating TP53 
mutations, possibly indicating that p53 inactivation might 
be a surrogate marker for chemoresistance of ROS1-positive 
tumors. Due to the small number of patients without benefit 
from chemotherapy, we did not check for a correlation 
of the percentage of translocated tumor cells and clinical 
outcome.
Supplementary Table 1 lists the used regimen and 
their outcomes. Noteworthy, while platinum/pemetrexed 
combinations showed high response rates with four 
out of five times used, the commonly used first-line 
therapy of platinum/paclitaxel only led to one response 
in six applications (see Supplementary Figure 3B and 
Supplementary Table 1). In all cases, treatment with 
erlotinib led to primary progression (n = 3). In three cases, 
progression developed under bevacizumab maintenance 
therapy after initial response (data not shown).
Five patients received crizotinib treatment; all of them 
responded impressively to monotherapy (see Figure 2C). 
So far only one patient died under therapy, whereas the 
remaining four are still ongoing under therapy.
DISCUSSION
To our knowledge, this study is the first analysis of 
Caucasian ROS1-rearranged patients demonstrating an OS 
advantage compared to other patients with NSCLC, even 
Pat ID Gender Age 
(years)
Initial 
stage
ROS1 
transl. 
(%)
Additional 
genetic 
aberration
Further 
analyzed
Pack-
years
Systemic 
therapy 
lines – CTX
BR 
CTX
Best 
response 
CTX under
BR 
crizotinib
Overall 
survival 
(months)
19 f 51 IV 96 -
EGFR, 
KRAS, 
BRAF, ALK
0 5 PR DOCE PR 33.25*
20 f 60 IV 70 -
EGFR, 
ALK, 
KRAS, 
BRAF, RET
0 3 PR CIS/PEM PR 27.67
Abbreviations: m = male, f = female; NGS = next-generation sequencing, FISH = flourescence in situ hybridization; CTX = 
chemotherapy, BR = best response, PR = partial response, SD = stable disease, PD = progressive disease; CARBO = 
carboplatin, GEM = gemcitabine, BEV = bevacitzumab, PEM = pemetrexed, RCTX = combined radio-chemotherapy, 
PACLI = paclitaxel, CET = cetuximab, DOCE = docetaxel.
*for OS: ongoing. NGS: panel with 102 amplicons and 14 genes.
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when compared to targeted-treated EGFR-mutated and/
or ALK-rearranged patients. Further, this analysis suggests 
a potential benefit of chemotherapy for this subgroup of 
NSCLC patients regarding OS and response and stays in line 
with recent reports of the high efficacy of crizotinib treatment 
for these patients [9, 14–17]. Taken together, due to high 
response rates under both “classic” cytotoxic therapy and 
targeted therapy with crizotinib for stage IV patients ROS1-
rearrangement seems to repesent one of the best prognostic 
factors in NSCLC reported so far. Estimated mean survival 
times for all patients are in the range of years, and until 
today, no median OS has been reached, neither for the entire 
population nor for the stage IV patients receiving crizotinib.
Due to its exploratory character, this analysis suffers 
some limitations: The number of patients described is small, 
and no power calculation has been performed a priori. By 
nature, all the analyses presented here were retrospective, 
and pooling the treatment regimens and the resulting 
response rates is not comparable to outcomes in prospective 
clinical trials. Nevertheless, given the low frequency of 1.8% 
in 1035 screened patients and the very recent discovery of 
this aberration, such retrospective analyses are needed to 
gain more insights in the clinical course of these patients. 
Clinical trials to evaluate the efficacy of crizotinb treatment 
prospectivly for patients with ROS1-rearrangement are 
ongoing, and these data will be available in the near future.
Importantly and in some contrast to published 
literature [9], our data show that ROS1-rearrangements 
are not mutually exclusive with other transformation-
associated genetic aberrations, as the majority of the 
patients presented with additional mutations. Beside 
mutations in BRAF, MET, and MAP2K1, we found 
a large variety of mutations affecting TP53. In two 
cases, truncating mutations of TP53 co-occurred with 
progressive disease under chemotherapy, whereof one 
patient, a 26-year old female patient, also presented with a 
partial neuroendocrine histology. Analysis of larger series 
of ROS1 positive patients in the future will elucidate 
whether these additional aberrations might play a role in 
the development of resistance.
Figure 2: (A) Overall survival of all patients with ROS1-rearrangement (n = 19). (B) Overall survival of stage IV with ROS1-
rearrangement (n = 14) and comparison with other genetically defined stage IV subgroups (n = 115). (C) Example of impressive metabolic 
response in a patient with ROS1-rearrangement treated with crizotinib at baseline and after two months of therapy.
Table 3: Summary of the subgroups used for comparison of OS
ROS1 EGFR EML4-ALK KRAS FGFR1
Patients (n) 14 38 13 32 32
Median age (range) 58 (25–87) 70 (30–86) 42 (28–70) 64 (35–83) 68 (47–80)
Median OS months 
(95% CI)
36.7 (n. a.) 25.3 (19.3–31.3) 23.9 (8.9–38.9) 6.6 (1.2–12.0) 11.0 (5.6–16.4)
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In ALK-rearaanged patients, pemetrexed is an 
efficient treatment choice [18]. While the efficacy 
of crizotinib in ROS1-rearranged patients has been 
recently shown [16], our dataset also suggests a benefit 
for pemetrexed-containing regimens in these patients. 
Therefore, drug development comprises both genetic 
subgroups [19]. Surprisingly, paclitaxel-containing 
platinum therapy seems to underperform in this patient 
group. Although the interpretation of this observation 
clearly is limited by the low patient number, it will be 
interesting to see if the choice of the primary platinum-
based chemotherapy regimen has an impact on outcome.
Taken together, ROS1-rearranged patients represent 
a unique subgroup of NSCLC patients, with a relatively 
good prognosis, a remarkable good outcome under different 
regimens of chemotherapy and dramatic responses under 
crizotinib. Future analysis will reveal more insights 
regarding the role of additional genetic aberrations in 
acquired resistance and differences in the efficacy of distinct 
chemotherapeutic regimens.
METHODS
Patients
This study was performed within a collaborative 
health care provider network for comprehensive 
molecular diagnostics of lung cancer in Cologne, Germany 
(Network Genomic Medicine [NGM], based at the Center 
for Integrated Oncology Köln-Bonn [CIO], Cologne, 
Germany), where samples of 1024 patients were analyzed, 
and in Barcelona, Spain, where 113 samples were screened 
for ROS1-status. The screening process was performed 
in order to detect patients who might participate in the 
aforementioned clinical trial. The trial has been approved 
by local auhorities and the responsible ethics committees. 
Screening procedures were conducted in concordance 
with the local ethical guidelines and were reviewed by the 
institutional ethics committee. All patients consented to 
be contacted after diagnosis and to provide information 
about the clinical history and outcome. Insight into their 
medical records was obtained. The present study covers 
a timeframe from August 2012 to April 2014. There was 
no preselection of patients regarding stage or clinical 
presentation.
Within the same timeframe, we collected data from 
patients without ROS1-rearrangement, who provided 
written informed consent to have their data analyzed, but 
with other defined aberrations. As ROS1-rearrangement 
most probably occurs in patients without smoking 
history [9], and given the fact that NSCLC in never-
smokers differs heavily from those of smokers in terms of 
mutational variability [20], we chose ALK-rearranged and 
EGFR-mutated patients with similar smoking habits as the 
best fitting control group. For both groups, patients were 
only taken into analysis if they had received treatment 
with at least one therapy-line with TKIs (i. e., erlotinib, 
gefitinib, afatinib, AZD9291 for EGFR, crizotinib and/or 
ceritinib for EML4-ALK), representing the subgroups of 
NSCLC patients so far with the best overall survival (OS) 
in stage IV NSCLC [7]. We also analyzed patients with 
KRAS mutations to provide a group without any targeted 
therapy option, and FGFR1-amplified squamous-cell 
carcinoma patients as a comparator smoking associated 
lung cancer [21].
Samples and immunohistochemistry
Tumor tissue was fixed in buffered formalin and 
embedded in paraffin blocks. All primary diagnoses 
were reviewed by two experienced pathologists. 
Morphologic features, e.g. size of nuclei, nucleus/
cytoplasm ratio and chromatin structure were evaluated 
on haematoxylin-eosin slides. To confirm the diagnosis 
ancillary immunohistochemical stainings were made, e.g. 
cytokeratins (CK5/6, CK7, p40) as well as TTF1 (thyroid 
transcription factor 1). Tumor diagnoses were made in 
accordance to the current WHO classification system [22].
FISH assay
For FISH, three to four μm tissue sections were 
mounted on sialinized slides and hybridized overnight 
with the ZytoLight© SPEC ROS1 Dual Color Break Apart 
Probe (ZytoVision, Bremerhaven, Germany). The 3` ROS1 
probe was labeled with ZyGreen™ and the 5` ROS1 probe 
was labeled with ZyOrange™. An exact protocol about the 
procedures is given in the supplementary file.
Tumors were defined as ROS1 rearranged when 
having ≥ 20% of tumor cells harboring aberrant signals.
Next-generation sequencing (NGS)
A more detailed protocol of tissue preparation for 
NGS is added as a supplementary file. Targeted next 
generation sequencing (NGS) was performed on all FFPE 
samples. Isolated DNA (< 0.5 – 200 ng/μl) was amplified 
with an in-house specified, customized Ion AmpliSeq 
Primer Pool (Lifetechnologies, Carlsbad, USA). The 
panel comprises 102 amplicons of 14 different genes. 
PCR products were ligated to adapters and enriched 
for target regions using the Ion AmpliSeq PanelTM 
Library kit according to manufacturer’s instructions 
(Lifetechnologies). The generated libraries were pooled 
equimolarly for amplicon sequencing to a concentration 
of 3 nM of each sample to counterbalance differences in 
sample quality. Sequencing was performed on the Illumina 
MiSeq benchtop sequencer (Illumina, San Diego, USA). 
Results were visualized in the Integrative Genomics 
Viewer (IGV) and then manually analyzed. A 5% cutoff 
for variant calls was used and results were only interpreted 
if the coverage was > 200.
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Clinical parameters
Age, gender, and tumor stage at diagnosis 
according to the UICC classification were assessed. 
Smoking status, medical history regarding past cancer 
therapies, and outcome to treatments were analyzed. 
For smoking status, pack-years were annotated. The 
following qualitative attribution was assessed: Patients 
with less than 100 cigarettes in their lifetime were 
considered as never smokers, patients with more than 
100 cigarettes, who quit smoking at least one year before 
first diagnosis of lung cancer were considered former 
smokers, and patients with a smoking history of more 
than one pack-year who continued smoking for a period 
shorter than one year before diagnosis were considered 
current smokers.
Statistics
Qualitative variables were summarized by count 
and percentage, quantitative variables (i.e. age) by mean, 
standard deviation, median and range. Distribution 
of time to event was described by the Kaplan-Meier 
curve and compared between groups by the log-rank 
test, giving the 95% confidence interval (95% CI). 
Association of qualitative variables was tested for by chi-
square or Fisher’s exact test, contingent on distributional 
assumptions. Overall survival (OS) was defined as the 
time period from the date of first diagnosis until death. 
Patients who were still alive at the data cut-off were 
censored.
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